An uncommon biotransformation of pyrimidine during the metabolism of GNE-892, a β-secretase 1 inhibitor, was investigated. Three novel metabolites, formed by conversion of pyrimidine to pyrazole, were observed in the 14 C-radiolabeled mass balance study in rats. Their structures were characterized by high-resolution mass spectrometry and NMR. Though these metabolites accounted for <5% of the administered dose, their unique nature prompted us to conduct further investigations. The pyrazole-containing metabolites were formed in vitro with rat hepatocytes and liver microsomes, which supported that they were formed during hepatic metabolism.
DMD #57141
Introduction GNE-892 ((R)-2-amino-1,3',3'-trimethyl-7'-(pyrimidin-5-yl)-3',4'-dihydro-2'H-spiro[imidazole-4,1'-naphthalen]-5(1H)-one) is a novel small molecule that was designed through structure-optimization efforts as a potent inhibitor for BACE1 (β-site amyloid precursor protein cleaving enzyme 1) (IC 50 48 nM, cellular IC 50 27 nM) (Hunt et al., 2013) . BACE1 is a protease that processes amyloid precursor protein to amyloid beta (Aβ) peptide fragments. The interaction of Aβ peptides with neurons has been implicated in neurodegeneration associated with the progression of Alzheimer's disease (Hardy and Higgins, 1992; Vassar et al., 1999) . ΒΑCE1 is, therefore, a promising protein target for the reduction of Aβ levels to interrupt or slow decline in neurocognitive function. The pharmacokinetics and pharmacodynamics of GNE-892 in cynomolgus monkeys provided proof of mechanism for β -secretase inhibition with significantly reduced levels of Aβ in plasma and cerebrospinal fluid following a single oral administration (Liu et al., 2013) .
GNE-892 was identified as a potential clinical candidate with promising absorption, distribution, metabolism, and excretion properties. In liver microsomes and hepatocytes, it was moderately stable for rat, and it was stable for monkey and human. The major metabolic pathways were N-demethylation, and hydroxylation at the oxo-imidazole or pyrimidyl-tetrahydro-naphthalene moieties. We recently reported the metabolism in cynomologus monkeys as being mainly oxidative and catalyzed not only by P450s, but also by aldehyde oxidase (manuscript submitted). Interestingly, the 14 C-radiolabeled metabolism study in monkeys, which was designed as proof-ofconcept for microdosing in humans, showed dose dependency in exposure and in the contributions by P450 and aldehyde oxidase to metabolism following single oral dosing.
DMD #57141 6 adjusted to pH 3.2 with ammonium hydroxide, and (B) MeOH. HPLC gradients were initiated with linear gradient from 15 to 35% B over first 10 min, then to 40% B at 11 min, and 100% B at 12 min. The column was washed with 100% B for 2 min before returning to the initial composition of 85% A for 2 min of equilibration before the next injection. The total sample run time was 16 min. The electrospray ion source voltage was set at 5.0 kV and heated capillary temperature at 350°C. A full-scan mass spectrum was acquired at a resolving power of 30,000 (at m/z of 400), and data dependent multi-stage mass spectrometry (MS n ) scans were acquired at a resolving power of 7,500.
Accurate mass measurements were performed using external calibration. Hydrogen-deuterium (H/D) exchange experiments were performed by replacing the aqueous and organic components of the mobile phases with deuterium oxide and MeOH-d 4 , respectively, and the number of exchanged protons was determined from the observed mass shift.
For plasma and in vitro sample metabolite radioprofiling, fractions of chromatography effluents were collected by with gentle shaking. Incubations were terminated with the addition of three volumes of ACN, samples were centrifuged, and the supernatants were concentrated and analyzed by LC-MS/MS and online radiodetection.
Separate incubations were conducted in the same manner with pre-incubation for 15 min with 1-aminobenzotriazole (1 mM), a nonselective P450 inactivator.
In vitro screening of rat P450 Supersomes (CYP1A2, 2C6, 2C11, 2C12, 2C13, 2D1, 2D2, 3A1, and 3A2) was performed using a constant amount of P450 (0.04 nmol/mL) supplemented with NADPH (1 mM) in potassium phosphate, pH 7.4 (100 mM), with magnesium chloride (3 mM) and GNE-892 (1 µM) for 60 min at 37ºC. For inhibition experiments, selective chemical inhibitors of CYP2D2 (fluoxetine, desipramine, quinine, and quinidine) at 10 µM were pre-incubated for 15 min at 37°C with NADPH (1 mM) and rat liver microsomes (0.5 mg/mL). The reaction was initiated with the addition of GNE-892 (1 µM) and lasted 60 min. At the end of the incubation, the reactions were quenched with an equal volume of cold ACN, and proteins were precipitated. Table 1 ). The majority of the radioactivity was recovered in feces (77%), and excretion was rapid and nearly complete after the first 48 h post-dose. For BDC rats, 53% of the administered radioactivity was excreted in bile and 33% in urine, which indicated that at least 86% of the dose had been absorbed.
Metabolite Identification. GNE-892 eliminated predominantly as metabolites that were oxidative in nature and in which the oxo-imidazole, dimethylcyclohexane, or pyrimidine moieties were modified ( Figure 1 and Table 2 ). The structures of metabolites were determined based on high-resolution full scan and MS n mass spectrometry experiments ( Figure 2 ). Since the focus of the described studies was the mechanism for the pyrimidine conversion to pyrazole, the structural elucidation descriptions provided here are only for metabolites where modifications of the pyrimidine moiety were identified.
This article has not been copyedited and formatted. The final version may differ from this version. Figure 2C ). The product ion at m/z 126 accounted for all of the carbons of an unchanged imidazole moiety, which suggested that the loss of carbon likely occurred at the pyrimidine moiety. H/D exchange indicated that M16 had three exchangeable protons, which was one more than the parent.
This implied the pyrimidine had been re-cyclized after the loss of carbon and this had introduced an exchangeable hydrogen. To confirm the structure of the five-membered ring moiety, M16 was isolated and purified from fecal samples and characterized by NMR ( Figure 3 and Table 3 ). In the 1 H NMR, a single signal at 7.84 ppm (2H, br s) was assigned to the two protons in the pyrazole ring. These two protons have similar electronic effects, yielding 
M21 had a [M+H]
+ at m/z 370.1881 (C 19 H 24 N 5 O 3 , 2.08 ppm), which was consistent with the addition of two oxygen and two hydrogen atoms to GNE-892. The product ion spectra showed a single abundant ion at m/z 325, generated by the loss of NH 2 C(O)H from the molecular ion ( Figure 2E ). Further dissociation of m/z 325 generated ions by fragmentation across the intact oxo-imidazole moiety, which were the primary fragmentation pathways observed for the molecular ions of GNE-892 and other metabolites. The favored loss of NH 2 C(O)H was rationalized to be a facile loss from an opened pyrimidine ring structure, where moieties formed by oxidative ring opening were aldehyde and N-hydroxy moiety.
Metabolic Profiles. The mean percentages of GNE-892 and its metabolites that were quantified in urine, feces, and bile, expressed as a percentage of the administered dose, are shown in Table 2 . The pyrimidine N-oxide metabolite M5 was detected in urine and feces accounting for 6.1 and 1.1% of the dose, respectively. The pyrazole metabolites M16 and M17 were observed in feces and accounted for 3.4 and 1.2% of the dose, respectively. The glucuronide conjugate of N-hydroxypyrazole metabolite, M14, was detected in bile and accounted for 3.2% of the dose. The pyrimidine-opened metabolite M21 was observed in urine and feces, though it was present at levels that were measureable by mass spectrometry and not by radiodetection.
This article has not been copyedited and formatted. The final version may differ from this version. Table 4 . At the end of the incubation, the pyrimidine-modified metabolites M5 and M14 had formed and accounted for 23.0 and 10.0% of the sample radioactivity, respectively. The remaining drug was converted to M1, M2, M4, M9, and M13, which were all modified at the dimethylcyclohexane by oxidative processes (Figure 1 ). These metabolites accounted for 12.9, 4.2, 16.8, 9.8, and 4.0% of the sample radioactivity, respectively, and the remaining radioactivity was distributed over other low-level analytes.
In Vitro Formation of Pyrazole Metabolites. Incubations of GNE-892 with nine major recombinant rat P450s demonstrated that CYP2D2 generated M17 to the greatest extent (Supplemental Figure 1) . By incubating GNE-892 in rat liver microsomes in the presence of CYP2D2 inhibitors, it was observed that desipramine and quinine were effective at inhibiting the formation of M17, while fluoxetine and quinidine were inhibitory to a lesser extent (16 and 55% of control, respectively) (Supplemental Figure 2) . These results were consistent with the reported potencies of these chemicals against rat CYP2D2 (Isobe et al., 2005; Makaji et al., 2010) . The residual formation of M17 in inhibition experiments could be attributed to the activity of CYP3A1, which also generated M17 as a recombinant enzyme, albeit to a lesser extent than CYP2D2.
In the incubation of [ 14 C]GNE-892 with recombinant CYP2D2, parent compound was rapidly converted to M5 such that after the first 15 min, unchanged GNE-892 was <5% and M5 was 95% (Figure 4 ). Through the remaining incubation, M17 was formed and its increase over time was stoichiometrically accounted by the decrease in M5. From 15 to 60 min, M5 decreased from 95 to 88% of the sample radioactivity, whereas M17 increased from 4 to 12%. M21 was also generated in this study, though only at levels detectable with mass spectrometry. No other metabolite was detected by radiodetection during the incubation.
In a two-step incubation, GNE-892 was incubated with recombinant CYP2D2 to generate M5. This reaction was quenched, then individual recombinant rat CYPs were added to the resulting incubate and M17 formation was monitored. Here, we observed that the addition of CYP2D2 was required for converting M5 to M17, and the other tested CYPs did not catalyze this reaction (data not shown).
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Discussion
In the characterization of the metabolism and excretion of GNE-892 in rats following a single oral dose, we identified three metabolites that were formed via conversion of the pyrimidine moiety to pyrazole structures.
Though examples of metabolic cleavage of pyrimidine exist, it is an uncommon biotransformation pathway (Prakash and Cui, 1997; Sharma et al., 2012) . Even more rarely observed has been re-cyclization following pyrimidine scission, which we have found described in only two other cases: (S)-25 and AZD3839 in rats (Lindgren et al., 2013) , and vicriviroc in humans (Ghosal et al., 2007) . In the cases of (S)-25 and AZD3839, the pyrimidine moiety was converted to imidazole and N-hydroxylated, N-oxidated, and conjugated derivatives in vivo in rats, but were not detected in vitro. In the case of the CCR5 receptor antagonist vicriviroc, the pyrimidine-4,6-dimethyl moiety was converted to a pyrazyl-hydroxylamine. Since, to the best of our knowledge, a mechanistic explanation for this pathway did not exist, and given the report for the metabolism of vicriviroc was precedence for this metabolic pathway in humans, we more closely investigated the pyrimidine conversion by conducting a series of in vitro metabolism studies with GNE-892. From these studies, we identified the enzyme responsible and immediate precursor for the pyrazole, and provide a proposed mechanism for this biotransformation.
The structure of the pyrazole metabolites of GNE-892 were elucidated by mass spectrometry and confirmed by NMR. These data were consistent with contraction of the pyrimidine ring to pyrazole and identified the structures of M16, M17, and M14 as the pyrazole, N-hydroxypyrazole, and glucuronide conjugate of the Nhydroxypyrazole, respectively. The apparent relationship between these metabolites was reinforced by their excretion profiles. M14 was found only in bile; whereas, in bile duct-intact animals, M14 was not present, but M16
and M17 were measured in feces. These results were consistent with M14 being secreted to the intestine in bile and undergoing β -glucuronidase-mediated cleavage to M17 and subsequent reduction to M16 during gastrointestinal transit. We also inferred based on M14 being found only in bile and the pyrazole metabolites not being detected in plasma that liver was likely the major organ for the formation of the pyrazole-containing metabolites.
Given that the pyrimidine conversion to pyrazole requires multiple steps, we sought to understand the enzymes that were involved. Rat hepatocytes were a complete in vitro metabolic system for this biotransformation and generated M14. 1-Aminobenzotriazole was effective at inhibiting this reaction, which indicated that P450s catalyzed at least one step in formation of the pyrazole. Incubation of GNE-892 with individual recombinant rat P450s revealed that CYP2D2 was most likely the rat P450 isoform responsible for the pyrazole formation. This was This article has not been copyedited and formatted. The final version may differ from this version. Most likely, a single oxidative step would not have converted the pyrimidine moiety to pyrazole; therefore, we aimed to identify the immediate precursor of the pyrimidine cleavage. Given that carbon-2 is lost from pyrimidine in its conversion to pyrazole, 2-hydroxypyrimidine was first considered as the precursor metabolite. For this purpose, a synthetic standard was tested in rat hepatocytes and liver microsomes; however, no pyrimidine ringopened or ring-contracted metabolite was detected. Another potential precursor was M5, pyrimidine N-oxide. M5
was an attractive source for the pyrazole metabolites given that it was observed in all samples in which these metabolites were present. Furthermore, it was the most abundant primary oxidative metabolite in rat in vivo and in vitro. Unfortunately, efforts to synthesize M5 were unsuccessful and we were unable to test it directly.
The evidence that M5 was likely the precursor metabolite of the pyrazole was provided by monitoring the formation of metabolites during the incubation of [ 14 C]GNE-892 with recombinant CYP2D2. In these incubations, [ 14 C]GNE-892 was rapidly and nearly quantitatively converted to M5. With continued incubation, M17 formed and mass balance of the radiolabelled material was only explained by accounting for M17 formation by decreases in M5; therefore, we concluded that M5 was the precursor of M17. In surveying these incubations for other drug-related analytes, we observed that M21 was also generated in this study, though it was present at low levels. In addition, when we tested if another P450 isoform could convert M5 to M17 by conducting a two-step incubation, only CYP2D2 was observed to catalyze this reaction.
Based on these findings, we propose the mechanism presented in Figure 5 for pyrimidine biotransformation to pyrazole by P450 enzyme. In the first step, the pyrimidine is oxidized to N-oxide (M5) by P450. Next, to open the pyrimidine ring and re-cyclize as pyrazole, we considered several possibilities for oxidizing M5 at carbon-2 of pyrimidine, which is ultimately lost. Though we did not attempt to study the oxygenating species in the P450-catalyzed reaction, there were observations for GNE-892 that provided us with some insight into this reaction. We first considered an oxo-iron species as an electrophilic oxidant since this is known to act in or, at least, can easily explain most known P450 oxidation reactions (Groves, 2005) . Oxidation of M5 by oxo-iron would result in epoxidation or hydroxylation, which is not typically known to lead to ring-opened metabolites. This was also supported by in vitro testing the 2-hydroxy metabolite and not detecting any ring-opened or pyrazole metabolites.
Further, it seemed inconsistent that hydroxylation of the N-oxide pyrimidine of M5, which is less electron rich than the pyrimidine of GNE-892, would occur with an electrophilic oxidant. Since the oxo-iron species did not adequately explain the P450-catalyzed reaction, an alternate oxidant, the peroxo-iron species (Fe-O-O -), was considered (Vaz, 2003) . The peroxo-iron species is nucleophilic in nature; therefore, this was consistent with the criterion that a more electron deficient species (N-oxide, M5) is the precursor required for opening the pyrimidine ring. Following formation of the peroxy complex, it seems reasonable that the C-N bond can be cleaved via heterolytic fragmentation and this opens the pyrimidine ring ( Figure 5 ). The resulting formamide intermediate can proceed through two possible pathways. In the first, the formamide intermediate is converted to M21 via a reductive reaction; though the low levels of this metabolite suggested that this is a less favored pathway. The more favored pathway was hydrolysis of the formamide moiety, which proceeds through losing formic acid in a cyclization reaction that forms N-hydroxypyrazole (M17). M17 could then be conjugated with glucuronic acid to form M14 or reduced to M16. As for previous reported examples, it is enticing to suggest that for vicriviroc, the pyrimidine Noxide and N-hydroxypyrazole metabolites that were observed are the precursor and product of pyrimidine conversion for that drug and that this reaction proceeds according to the same or a similar mechanism in humans as we propose here for GNE-892.
The examples of pyrimidine biotransformation to pyrazole, such as GNE-892, vicriviroc, and (S)-25, demonstrate the potential for carbon atom loss via oxidative biotransformation. This should be considered when selecting the placement of a 14 C radiolabel for metabolism studies (Penner et al., 2012) . To date, this biotransformation has been a minor component of total reported metabolism; however, it is conceivable that for other chemicals it occurs to a much greater extent depending on structure, enzymology, or test species. Without a prior knowledge to design experiments that retain volatile components, loss of the radiolabel would result in lower mass balance and a metabolic pathway would not be identified (Roffey et al., 2007) . This biotransformation should also be considered in non-radiolabeled studies, especially when human metabolites are being identified for consideration of safety testing. Without a radiolabel to indicate the drug-derived analytes, it is necessary to utilize workflows that search for common and uncommon metabolites. This requires a comprehensive knowledge of possible biotransformations, and underscores the importance of studying the structural requirements, enzymology, and mechanisms of uncommon pathways once they are discovered.
This article has not been copyedited and formatted. The final version may differ from this version. GNE-892, M5, M17, and M21 were observed at 8.1, 4.9, 10.7, and 10.9 min, respectively. Urine and bile were 0-24 h, feces were 0-48 h. ND, not detected; D, detected by mass spectrometry b The signal was in the shoulder of the solvent residual peak.
